Edwards Lifesciences RESILIA Tissue Shows 10-Year Durability in COMMENCE Aortic Trial Results

Key Takeaways

• Edwards Lifesciences RESILIA tissue demonstrates sustained performance and durability over 10 years in pivotal COMMENCE aortic trial
• Long-term data supports the tissue’s effectiveness for patients requiring aortic valve replacement procedures
• Results presented at 106th American Association for Thoracic Surgery Annual Meeting strengthen evidence base for structural heart interventions

---

Edwards Lifesciences Corporation announced compelling 10-year results from the COMMENCE aortic trial, demonstrating the sustained durability and performance of its proprietary RESILIA tissue technology. The data were presented at the 106th American Association for Thoracic Surgery Annual Meeting in Singapore on May 4, 2026.

Trial Results Strengthen Evidence Base

The decade-long follow-up data from the COMMENCE trial provides crucial evidence for the long-term effectiveness of Edwards’ RESILIA tissue in aortic valve replacement procedures. This extended evidence base represents a significant milestone for patients and clinicians seeking durable treatment options for structural heart disease.

Edwards Lifesciences, recognized as the leading global structural heart innovation company, has been advancing cardiovascular care through its tissue engineering technologies. The RESILIA tissue incorporates proprietary processing techniques designed to enhance durability and reduce calcification, common concerns in tissue-based heart valve replacements.

Market Impact and Clinical Significance

The 10-year durability data positions Edwards favorably in the competitive structural heart market, where long-term performance is critical for patient outcomes and physician confidence. These results may influence treatment guidelines and support broader adoption of RESILIA tissue-based solutions.

For patients with aortic valve disease, the extended durability data provides reassurance about the longevity of their treatment option. The sustained performance over a decade addresses key concerns about tissue valve longevity that often influence treatment decisions between surgical and transcatheter approaches.

Future Implications

The robust 10-year data strengthens Edwards’ position in the structural heart market and may support regulatory submissions and clinical adoption globally. The company continues to advance its tissue technologies as part of its broader structural heart portfolio, which includes transcatheter aortic valve replacement (TAVR) systems and surgical heart valves.

---

Frequently Asked Questions

What does this mean for patients needing aortic valve replacement?

The 10-year durability data provides strong evidence that RESILIA tissue maintains its performance over an extended period, offering patients confidence in the longevity of their valve replacement treatment.

How significant is 10-year durability data for heart valve technology?

Ten-year data is considered highly significant in cardiovascular medicine as it demonstrates long-term safety and effectiveness, which is crucial for devices intended to last decades in patients.

What makes RESILIA tissue different from other heart valve materials?

RESILIA tissue uses Edwards’ proprietary processing technology designed to reduce calcification and enhance durability compared to traditional tissue processing methods used in heart valve manufacturing.